Watchlist Price Alert

Simulations Plus Inc. (SLP)

NASDAQ: SLP · Real-Time Price · USD

18.96

-0.11 (-0.58%)

At close: Jun 16, 2025, 3:59 PM

18.98

0.11%

After-hours: Jun 16, 2025, 07:47 PM EDT

-0.58% (1D)

Bid	18.69
Market Cap	381.3M
Revenue (ttm)	78.56M
Net Income (ttm)	7.22M
EPS (ttm)	0.36
PE Ratio (ttm)	52.67
Forward PE	15.21
Analyst	Buy

Ask	19.98
Volume	417,070
Avg. Volume (20D)	382,801
Open	19.23
Previous Close	19.07
Day's Range	18.79 - 19.50
52-Week Range	18.66 - 49.71
Beta	0.97

About SLP

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SLP

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SLP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

+26.85%

Shares of healthcare technology stocks are trading... Unlock content with Pro Subscription

2 months ago

+0.74%

Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

News

3 days ago · seekingalpha.com

Simulations Plus: Further Downside Is Likely (Rating Downgrade)

Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and th...

5 days ago · benzinga.com

Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt

Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.

4 days ago · zacks.com

SLP Cuts FY25 Revenue Outlook, Begins Strategic Reorganization

Simulations Plus lowers FY25 revenue forecast and restructures operations as biotech headwinds hit services demand.

5 days ago · businesswire.com

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

6 days ago · businesswire.com

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled perf...

1 week ago · businesswire.com

Simulations Plus Releases ADMET Predictor® 13

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

4 weeks ago · zacks.com

SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?

Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.

Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, incl...

Load More News